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Protocol
AbstrACt
Introduction Phantom limb pain (PLP) is a chronic 
condition that can greatly diminish quality of life. Control 
over the phantom limb and exercise of such control have 
been hypothesised to reverse maladaptive brain changes 
correlated to PLP. Preliminary investigations have shown 
that decoding motor volition using myoelectric pattern 
recognition, while providing real-time feedback via virtual 
and augmented reality (VR-AR), facilitates phantom motor 
execution (PME) and reduces PLP. Here we present the 
study protocol for an international (seven countries), 
multicentre (nine clinics), double-blind, randomised 
controlled clinical trial to assess the effectiveness of PME 
in alleviating PLP.
Methods and analysis Sixty-seven subjects suffering 
from PLP in upper or lower limbs are randomly assigned 
to PME or phantom motor imagery (PMI) interventions. 
Subjects allocated to either treatment receive 15 
interventions and are exposed to the same VR-AR 
environments using the same device. The only difference 
between interventions is whether phantom movements 
are actually performed (PME) or just imagined (PMI). 
Complete evaluations are conducted at baseline and at 
intervention completion, as well as 1, 3 and 6 months 
later using an intention-to-treat (ITT) approach. Changes 
in PLP measured using the Pain Rating Index between the 
first and last session are the primary measure of efficacy. 
Secondary outcomes include: frequency, duration, quality 
of pain, intrusion of pain in activities of daily living and 
sleep, disability associated to pain, pain self-efficacy, 
frequency of depressed mood, presence of catastrophising 
thinking, health-related quality of life and clinically 
significant change as patient’s own impression. Follow-
up interviews are conducted up to 6 months after the 
treatment.
Ethics and dissemination The study is performed in 
agreement with the Declaration of Helsinki and under 
approval by the governing ethical committees of each 
participating clinic. The results will be published according 
to the Consolidated Standards of Reporting Trials 
guidelines in a peer-reviewed journal.
trial registration number NCT03112928; Pre-results.
IntroduCtIon  
Phantom limb pain (PLP) is a chronic condi-
tion commonly suffered by amputees.1 2 
Although more than 60 different treatments 
to alleviate PLP have been described in the 
literature,3 controlled clinical trials on such 
treatments are scarce and tend to be of poor 
quality.4 The clinical investigation presented 
in this protocol aims to evaluate the effi-
cacy of phantom motor execution (PME) 
in reducing PLP in an international, multi-
centre, double-blind, randomised controlled 
clinical (RCT) trial. PME is accomplished by 
using a system (Neuromotus, Integrum AB, 
Sweden) that employs myoelectric pattern 
recognition to predict motor volition (move-
ments of the phantom limb) while providing 
real-time feedback to the patient in virtual and 
augmented reality (VR/AR) environments. 
strengths and limitations of this study
 ► This study involves a   suitable number of partic-
ipants (>60) to provide the power necessary for 
meaningful conclusions. 
 ► This study is double-blinded, randomised  con-
trolled clinical trial, conducted in geographically 
different locations and involves subjects with both 
upper and lower limb amputations, thus enhancing 
generalisability.
 ► The choice of the comparator allows controlling in a 
stringent manner for the effect of the key factor hy-
pothesised as the cause of pain reduction, namely, 
the execution of phantom limb movements.
 ► Treatment is limited to 15 sessions, which might not 
be enough to alleviate pain in all participants.
 ► The nature of the experimental treatment (phantom 
motor execution) does not allow inclusion of indi-
viduals from which myoelectric signals cannot be 
recorded from the muscles in their residual limbs.
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This technology allows the application of serious gaming 
in the therapy. PME is a non-invasive, non-pharmaco-
logical and engaging treatment with no identified side 
effects at present.5 6 
The effectiveness of PME was initially explored in 
a single upper limb amputee, with satisfactory results 
reported.5 Prior to the pilot study, the patient had shown 
resistance to a variety of treatments for 48 years (including 
mirror therapy). After PME, the sustained level of pain 
reported by the patient was gradually reduced to pain-
free periods. He and his family also reported less intru-
sion of PLP in sleep and activities of daily living (ADLs). 
Finally, the patient also acquired the ability to freely move 
his phantom arm and hand, consistent with a recent study 
by Raffin and colleagues7 where they found that reduced 
capability of phantom movement was correlated with 
more severe PLP.
In the light of the findings in the case study, a non-ran-
domised clinical investigation on PME was conducted in 
subjects with chronic intractable upper limb PLP.6 Four-
teen patients, for whom conventional PLP treatments 
failed and who suffered from PLP for an average of 10 
years, received 12 treatment sessions of PME, each of 
1.5-hour duration. At the end of the treatment period, 
patients showed statistically and clinically significant 
improvements (approximately 50% reduction of PLP). 
Intrusion of PLP during sleep and ADL was also reduced 
by a similar degree. These improvements were still 
present up to 6 months’ post-treatment.6 More recently, 
PME was also demonstrated to be a viable treatment for 
PLP in lower limb amputations.8
Strong evidence shows that PLP is related to neuro-
plastic changes in the primary somatosensory cortex, 
suggesting that central maladaptive plasticity is 
responsible for its maintenance. Neuroplasticity-based 
approaches for the relief of PLP, such as motor imagery 
and mirror therapy, ultimately aim to regain brain 
circuitry from pain processing. Nonetheless, these 
approaches have been shown to be limited in their 
effectiveness.
Although the practice of motor imagery has been shown 
to normalise previously altered cortical maps and reduce 
PLP,9 evidence from randomised clinical studies has also 
suggested that it can increase pain.10 These seemingly 
contradictory findings suggest that motor imagery should 
not be used alone but combined with other interventions, 
such as graded motor imagery11 or mirror therapy.12
Mirror therapy has demonstrated higher effectiveness 
than motor imagery in reducing pain10; however, it still 
cannot ensure that the patient performs movements 
with the phantom limb. For instance, it is enough for 
the patient to move their healthy arm to produce move-
ment in the reflected limb. Whether a patient is actually 
engaging in execution of phantom limb movements is 
unknown. PME overcomes some of the methodolog-
ical limitations of previous treatments by ensuring that 
central and peripheral mechanisms in motor control are 
activated during therapy.
study objECtIvE
This paper presents the study protocol for a RCT in which 
upper and lower limb amputees are treated. The inves-
tigation primarily aims at assessing the efficacy of PME 
aided by myoelectric pattern recognition, VR/AR and 
serious gaming to reduce PLP. In order to isolate the 
contribution of PME in alleviating PLP over potential 
placebo effects, phantom motor imagery (PMI) is used in 
this study as an active control treatment.
The working hypothesis of PME is that execution of 
phantom limb movements would exploit competitive 
neuroplasticity and provide a more integral normalisation 
of cortical, subcortical and spinal circuits compared with 
interventions that do not enable integration of sensory 
and motor information. Therefore, in this superiority 
trial, we hypothesise that the participants receiving the 
experimental treatment (PME) to obtain a larger reduc-
tion in PLP levels than those randomised to the control 
treatment.
trIAl dEsIgn
This clinical study is an international, multicentre, double-
blind, randomised controlled trial. The study takes place 
in seven counties and involves nine clinics, which are listed 
in table 1. Participants are randomly assigned to receive 
either the experimental or the control treatment in a 2:1 
allocation ratio. The choice of the allocation ration was 
made in order to collect more data on the intervention 
of interest. Each patient is followed up for a period of 
6 months, at the end of which they are given the choice to 
undergo the alternative treatment. The total duration of 
the study is expected to be approximately 3 years.
Table 1 List of the investigational sites, divided by 
countries taking part to the international, multicentre 
randomised clinical trial
Country Investigational site
Sweden Sahlgrenska University Hospital, Gothenburg
Örebro University Hospital, Örebro
Rehabcenter Sfären, Bräcke Diakoni, 
Stockholm
Slovenia University Rehabilitation Institute, Ljubljana
Belgium Fysische Geneeskunde en Revalidatie 
University Hospital Gent, Gent
The 
Netherlands
Department of Rehabilitation Medicine, 
University Medical Centre Groningen, 
Groningen
Canada Institute of Biomedical Engineering, University 
of New Brunswick, New Brunswick
Ireland Centre for Pain Research, National University 
of Ireland, Galway
Germany Department of Psychosomatic Medicine and 
Psychotherapy, LWL University Hospital, 
Ruhr-University Bochum, Bochum
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MEthods: pArtICIpAnts, IntErvEntIons, And outCoMEs
A procedural overview of the trial is provided by the flow 
diagram of figure 1. Recruitment of the participants 
is conducted via advertisements at local investigation 
clinics, on social media and in local newspapers. People 
who are interested in taking part in the trial are invited to 
contact the principal investigator of the site, or a person 
appointed by the principal investigator, via phone or 
email.
Eligibility criteria
Interested people are invited to a preassessment visit (visit 
0). On this occasion, the therapist (clinical investigator) 
explains the study in detail and answers all the questions 
that might arise. Afterwards, the participants are asked 
to provide written informed consent (see supplementary 
appendix A). If consent is granted, eligibility to the study 
is assessed according to the criteria presented below:
 ► The participants must be older than 18 years with 
chronic PLP.
 ► Participants must have chronic PLP—at least 6 months 
should have passed since amputation. Participants 
with acute PLP are non-eligible.
 ► In case of pharmacological treatments, the dosage 
must have been stable for the previous month.
 ► Any previous PLP treatments must have terminated at 
least 3 months prior to entering the study.
 ► Any pain reduction potentially attributable to previous 
PLP treatments must have occurred at least 3 months 
prior to entering the study.
 ► Voluntary control over at least a portion of biceps 
and triceps muscles in case of upper limb amputation 
or quadriceps and hamstrings in case of lower limb 
amputation.
 ► Stable prosthetic situation (ie, satisfaction with the 
fitting of the prosthesis) or being a non-user.
Figure 1 Flow diagram for the randomised controlled clinical trial. At least 67 patients are recruited and randomly allocated 
to either phantom motor execution (PME) or phantom motor imagery (PMI) interventions in allocation ratio 2:1. Following the 
completion of the treatment protocol and wash-out period of 6 months, it is possible for the patient to cross over to the parallel 
interventional arm, according to their will.
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 ► The subject should not have a cognitive impairment 
that prevents them from following instructions.
 ► No abundant soft tissue on the stump that prevents 
sufficient myoelectric signals from being recorded.
 ► No presence of pain >2 on Numerical Rating Scale 
(NRS) on contact with the skin or muscle contraction 
in the stump.
 ► The PLP must not be aggravated (NRS >4) by the 
execution or imagination of phantom movements.
 ► No condition associated with risk of poor protocol 
compliance.
 ► No injury, disease or addiction that would render the 
individual unsuitable for the trial.
 ► Pain Rating Index (PRI) >0 as assessed in the Ques-
tionnaire for Phantom Limb Pain (Q-PLP) at visit 0.
Concomitant medications
Any cointervention aiming to reduce PLP is prohibited 
during the trial. However, in the design of the trial, it is 
acknowledged that there is a large possibility for patients 
with PLP to be high consumers of analgesic medicines. 
Therefore, the use of concomitant medications is allowed 
provided that at the time of inclusion, the patient has 
stable consumption for at least 1 month before entering 
the study and any pain reduction potentially attributable 
to the drug occurred at least 3 months before entering 
the study. Intake of pain medication in patients who show 
considerable improvement can be gradually reduced at 
the discretion of the responsible physician, given that 
the patient is followed up regularly. Medication intake is 
thus monitored as an outcome variable called ‘need of 
concomitant medication’, which is used to describe and 
compare the amount of comedication in the treatment 
groups.
Interventions
All of the therapists at the clinics are introduced to the 
technology with at least one practical demonstration by 
the first (EL) and/or last author (MO-C). The therapists 
conduct the interventions independently, and periodi-
cally the first author monitors the correct execution of the 
protocol. Participants in both intervention groups receive 
15 treatment sessions of 2 hours’ duration, including 
system setup and a blinded outcome assessment. The 
frequency of the sessions is chosen by the participant 
and can be once, twice (advised frequency) or five times 
per week, yielding a total patient duration that ranges 
between 28 and 40 weeks. Both treatment groups use the 
same device and setup, which are sketched in figure 2. 
The only difference between the two groups is the type of 
interaction with the virtual environments (active: motor 
execution; or passive: motor imagery). Allocated inter-
ventions for a given trial participant cannot be modified. 
Dates of the treatment sessions are recorded.
Experimental treatment
In the PME intervention, motor volition is decoded by 
interpreting the signals from the stump muscles via 
myoelectric pattern recognition.13 14 The decoded move-
ment is visualised in the virtual environments (ie, virtual 
limb or serious gaming). The end result is that the user, 
by training with the system, can achieve control over the 
virtual environments by performing phantom limb move-
ments associated with kinetic sensations analogous to the 
ones pertaining to the limb prior to amputation.
A treatment session consists of the following steps:
1. Placement of the electrodes and fiducial marker.
2. Treatment cycles
a. Recording session.
b. Practice of PME with VR/AR.
c. Serious gaming using phantom movements.
d. Practice of PME by matching random target pos-
tures of a virtual arm in VR (TAC Test15).
3. Pain evaluation (Q-PLP; see Outcomes section).
Different treatment cycles (step 2) are repeated during 
a treatment session in order to execute various phantom 
limb movements or combinations of movements. The level 
of difficulty gradually increases during the treatment phase 
from 1 to 5 by adding df to be trained within the same treat-
ment cycle. In this context, a df is any pair of movements 
performing opposite actions such as opening and closing of 
the hand or extension and flexion of the knee.
Clinicians are instructed to advance the level of diffi-
culty once the previous level is accomplished success-
fully and revert to the previous level if the patient shows 
considerable difficulty accomplishing the tasks. More 
details on the acquisition of myoelectric signals, predic-
tion of motor volition, the various parts of the treatment 
session and the different levels of difficulty are presented 
in online supplementary appendix B.
Control treatment
In the control treatment (PMI), patients are not allowed 
to produce/execute phantom movements, but must 
imagine performing such movements while observing them 
Figure 2 Schematic illustration of the clinical investigation 
device with all its components. Myoelectric signals are 
acquired though surface electrodes (A) by a myoelectric 
amplifier (B), electrically isolated (C). The signals are then 
processed by the software installed on the computer (D). The 
camera (E) films the participant and the recorded image is 
displayed on the monitor (F) with a virtual limb superimposed 
where the marker (G) is detected. Figure courtesy of Jason 
Millenaar.
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executed autonomously by the VR/AR environments. The 
device is identical to the one used in the experimental treat-
ment, but here the myoelectric signals are used to monitor 
that the patient does not produce muscular contractions, 
rather than decoding motor volition.
The control treatment session is conducted using the 
same stepwise procedure as the experimental group 
with the addition of a calibration step at the beginning 
of the treatment cycle. Calibration is necessary to set the 
threshold for myoelectric signals above, which the system 
alerts the user that a muscular contraction is performed. 
As in PME, the treatment cycle is repeated for different 
imaginary phantom limb movements or a set of imaginary 
movements following the same levels of difficulty. In the 
game format, the participants control the game using the 
keyboard with an able limb. Bilateral upper limb amputees 
use a joystick with any able limb. Details on the methods 
are presented in online supplementary appendix B.
Withdrawal or termination of individual participants
Participants are free to withdraw from participation in the 
study at any time on request. An investigator may termi-
nate participation in the study if:
 ► Any clinical adverse event, clinical abnormality or 
other medical condition or situation occurs such that 
continued participation in the study would not be in 
the best interest of the participant.
 ► The participant no longer meets the eligibility criteria 
because of a condition newly developed or not previ-
ously recognised.
The main analysis will be conducted using the inten-
tion-to-treat (ITT) methodology. Missing data due to 
withdrawal or termination will be imputed using the ‘last 
observation carried forward’ method. From previous 
studies, the dropout rate is estimated at approximately 
10%, and this was taken into account for the calculation 
of the sample size.
outcomes
Outcomes will be evaluated at every treatment session 
and three follow-up assessments at 1, 3 and 6 months’ 
post-treatment. The outcomes are measured by the 
evaluators following the participant treatment schedule 
presented in table 2.
Primary outcome measure
The primary outcome of the study is the change in PLP 
intensity measured by the difference in PRI between base-
line (visit 0) and at the post-treatment assessment (visit 
15). The PRI is computed as the sum of the scores for all 
descriptors of the Short Form of the McGill Pain Ques-
tionnaire (SF-MPQ).16 Within this study, the SF-MPQ is 
included in one more extensive survey named Question-
naire for Phantom Limb Pain, which is described below 
in the secondary outcome measures.
Secondary outcome measures
Secondary outcomes consider different aspects related 
to PLP such as pain frequency, pain duration, quality 
of pain, intrusion of pain in ADLs and sleep, disability 
associated with pain, pain self-efficacy, mood, presence 
of catastrophising thinking, health-related quality of life 
and the patient’s own impression about the effect of treat-
ment. The secondary outcome measures are:
Pain Disability Index (PDI)
PDI, a seven-item questionnaire designed to investi-
gate the extent to which chronic pain interferes with a 
person’s ability to engage in various life activities.17 An 
Table 2 Summary of the different items (intervention, forms 
and questionnaires) to be completed at each evaluation 
appointment
Session Summary of content
Visit 0  ► Patient information (T).
 ► Study consent (T).
 ► Preassessment (T).
 ► Background information (T).
 ► Q-PLP (T).
 ► PDI (T).
 ► EQ5D-5L (T).
 ► PSEQ-2 (T).
 ► PCS-SF (T).
 ► PHQ-2 (T).
 ► EXPECT-SF (T).
Randomisation
Visit 1  ► Treatment session (T).
 ► Q-PLP (E).
 ► OAT (E).
 ► EXPECT-SF (E).
 ► HCCQ-SF (E).
Visits 2–14  ► Treatment session (T).
 ► Q-PLP (E).
Visit 15  ► Treatment session (T).
 ► Q-PLP (E).
 ► PDI (E).
 ► EQ5D-5L (E).
 ► PSEQ-2 (E).
 ► PCS-SF (E).
 ► PHQ-2 (E).
 ► PGIC (E).
 ► HCCQ-SF (E).
1-month follow-up  ► Q-PLP (E).
 ► PDI (E).
 ► EQ5D-5L (E).
 ► PSEQ-2 (E).
 ► PCS-SF (E).
 ► PHQ-2 (E).
3-month follow-up
6-month follow-up
The letter in brackets indicates whether the therapist (T) or the 
evaluator (E) is responsible of conducting a particular item is
EQ-5D-5L, EuroQol-5D-5L; EXPECT-SF, Expectations for 
Complementary and Alternative Medicine Treatments Short Form; 
HCCQ, Health Care Climate Questionnaire; OAT, Opinion About 
Treatment; PCS-SF, Pain Catastrophizing Scale Short Form; PDI, 
Pain Disability Index; PGIC, Patients’ Global Impression of Change; 
PHQ-2, two-item Patient Health Questionnaire; PSEQ-2, two-
item Pain Self-Efficacy Questionnaire; Q-PLP, Questionnaire for 
Phantom Limb Pain. 
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overall PDI score is obtained by summing the numerical 
ratings of the questionnaire’s single items.
Questionnaire for Phantom Limb Pain
The Q-PLP is a 16-item questionnaire based on a combi-
nation of the SF-MPQ16 and study-specific questions use 
in previous studies.5 6 8. The part containing the SF-MPQ 
is used for the calculation of the PRI (primary outcome 
measure).
The Q-PLP assesses intensity, quality, duration and 
frequency of PLP using the following metrics: the 
numeric rating scale (scale range 0–10) to assess the 
intensity of pain at present; the weighted pain distribu-
tion (scale range 0–5) to capture the time-varying nature 
of chronic pain by adding the contributions of weighted 
portions of time spent in six pain levels (present pain 
intensity scale,18); and a study-specific descriptive scale of 
seven steps: ‘never’, ‘once per month’, ‘once per week’, 
‘few times per week’, ‘once per day’, ‘few times per day’ 
and ‘always’ to measure the frequency of pain.
In addition, the Q-PLP is used to monitor the inten-
sity of stump pain, phantom limb sensations, phantom 
motor ability, intrusion of PLP in ADLs and sleep, by one 
question each using a numeric rating scale. Changes in 
prosthetic hardware, medication, presence of telescoping 
(feeling that the phantom limb is gradually shortening 
over time) and location of pain are also monitored by the 
Q-PLP.
EuroQol-5D-5L (EQ-5D-5L)
The EQ-5D-5L is a standardised questionnaire used to 
investigate health-related quality of life, which is consti-
tuted by two components: health status and health 
evaluation.19 Health status is measured in terms of five 
dimensions (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) on a five-point scale 
(no problems, slight problems, moderate problems, 
severe problems and extreme problems). In the health 
evaluation part, the EQ Visual Analogue Scale records 
the respondent’s health on a vertical VAS where the end 
points are labelled ‘best imaginable health state’ and 
‘worst imaginable health state’.
Pain Self-Efficacy Questionnaire (PSEQ-2)
The PSEQ-2 is a two-item questionnaire that measures pain 
self-efficacy, which is the belief held by people with chronic 
pain that they can carry out certain activities and enjoy life, 
despite experiencing pain.20 21 The items of the question-
naire are rated on a numeric rating scale from 0 to 6.
Pain Catastrophizing Scale – 6 (PCS-6)
The PCS-6 is a six-item questionnaire that investigates 
catastrophising thinking in a range from 0 to 4.22 23 
Pain catastrophising denotes a negative cognitive-affec-
tive response to pain and is associated to increased pain 
severity, disability and depressive symptoms and is associ-
ated with poor adjustment to chronic pain.24
Patient Health Questionnaire-2 (PHQ-2)
The PHQ-2 is a screening instrument consisting of two 
items assessing the presence of a depressed mood and a 
loss of interest or pleasure in routine activities.25 26 The 
items of the questionnaire are rated on a numerical scale 
from 0 to 3.
Patients’ Global Impression of Change (PGIC)
The PGIC is a single question used to identify clinically 
significant change by rating the patient’s belief about the 
efficacy of treatment on a seven-point scale, ranging from 
‘no change (or condition has got worse)’ to ‘a great deal 
better’.27
Additional measurements
Participants are asked to supply details regarding back-
ground information such as age, gender, height, weight, 
type and use of the prosthesis, level of embodiment of 
the prosthesis, onset of PLP, details about previous and 
ongoing intervention for PLP and side, level and date 
of amputation. Additionally, we also survey: patients’ 
expectancy of benefit using the Expectations for 
Complementary and Alternative Medicine Treatments 
(EXPECT-SF)28; patients’ judgement about the cred-
ibility of the treatment using the Opinion About Treat-
ment (OAT)29 and patients’ perception of therapists’ 
supportive behaviour using the short form of the six-item 
Health Care Climate Questionnaire (HCCQ).30
Sample size
The calculation of the sample size was based on our 
primary hypothesis and informed by our previous clin-
ical trial with no control group.6 In order to find a mean 
difference of 4 between the two randomised groups in 
the primary outcome measure (PRI), with power of 
80% resulting from a two-sided Fisher’s non-parametric 
permutation test at 5% significance level, is estimated that 
at least 60 participants are required. As a drop-out rate of 
10% is expected, a total of 67 patients will be randomised.
MEthods: AssIgnMEnt of IntErvEntIon
randomisation
Participants are assigned to the experimental or control 
group according to the optimal allocation scheme of 
minimisation, aimed at reducing the imbalance between 
the number of patients allocated to each treatment 
group. The randomisation proportion is 2:1, with twice 
as many subjects assigned to the experimental treatment. 
The allocation ratio was chosen to collect more informa-
tion on important variables regarding the intervention of 
interest. The allocation aims to minimise the imbalance 
of the following factors:
 ► Level of amputation (upper and lower).
 ► Baseline PLP based on the NRS (low 1–4, and high 
5–10).
 ► Investigation site (nine centres).
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The minimisation process is conducted using the open-
source desktop application MinimPy,31 operated by the 
monitor of the clinical trial. Every time a research team at a 
particular investigational site recruits a new participant, they 
assess the person’s eligibility for the study (visit 0). After-
wards, if the participant is deemed eligible, the research 
team sends the minimisation factors relative to the enrolled 
participant to the monitor, who runs the randomisation and 
informs the research team of the allocation.
blinding
This investigation has been designed in such a way that 
participants of the two treatment groups use the same 
device under the same circumstances.
Even though the patients are necessarily aware of the 
treatment they are receiving, they do not have an expec-
tation of superiority of the experimental over the control 
treatment (or vice versa), since the trial is framed as a 
comparison between two different interventions previ-
ously described in the literature. It is worth noting that 
the distinction between motor execution and motor 
imagery is often imperceptible, even for professionals 
in the field, who have often described voluntary move-
ments of the missing limb as imaginary movements.9 32–37 
We take this fact as a corroborant of our assumption 
that there are no differences at baseline with respect to 
expectations and opinions about the assigned treatment 
among participants. Nevertheless, individuals’ expecta-
tions regarding outcomes and credibility of the assigned 
treatment are assessed with the EXPECT-SF and the OAT 
questionnaires, respectively.
The nature of the investigation does not allow the 
masking of the treatment for the therapists. However, it is 
still important to check for possible differences between the 
two groups concerning the therapists’ supportive behaviour. 
For this reason, the HCCQ, is included as a measure of the 
extent to which a healthcare provider (or the staff) interacts 
with their patient in a supportive manner.
The outcome assessments are conducted by indepen-
dent persons who are blinded to the group allocation, 
making the trial double blind. In order to keep group 
allocation confidential, participants are requested prior 
to each assessment not to reveal allocation or therapy 
content to the evaluators.
The raw data resulting from the outcome assessment 
has the same structure for both interventions, making it 
impossible to tell the group assignment without being in 
possession of the documents containing links between 
participant’s identity and their code number.
MEthods: dAtA CollECtIon, MAnAgEMEnt And AnAlysIs
data collection and management
The monitor of the study (EL) is in charge of over-
seeing the progress of the RCT and ensuring that it is 
conducted, recorded and reported in accordance with 
the protocol, Good Clinical Practice (GCP) and regula-
tory requirements.
The monitor supplies case report forms (CRFs), which 
are filled in by the evaluator at each site. The evaluator 
is responsible to document all data obtained during the 
study, which is identified by participant code number. 
This also applies to data for patients who, after having 
consented to participate, undergo the baseline examina-
tions required for inclusion in the study, but who are not 
included. No items in the CRF are to be left unattended: 
if data are missing or are impossible to obtain, these 
should be documented as ‘not available’ (NA) and the 
reasons for missing data must be noted in the document.
All data are recorded and stored in digital form on 
encrypted electronic devices. Documents containing 
links between a participant’s identity and their code 
number exist only in paper form and are kept in locked 
file cabinets with limited access at the investigation site 
where the participants have been treated. In accordance 
with the regulations issued by The Swedish Data Protec-
tion Authority, a personal register will be established.
The clinical investigators are responsible to probe, via 
discussion with the participant, for the occurrence of 
adverse events during each visit and record the informa-
tion in the patient CRF. Adverse events must be described 
by duration (start and stop dates and times), severity, 
outcome, treatment and relation to study device, or if 
unrelated, the cause. The investigator must report any 
reportable event to the monitor in acceptable timely 
conditions, but not later than three working days after 
the occurrence of the event.
The sponsor must report to the Medical Products 
Agency (Läkemedelsverket) any serious adverse event, 
which indicates an imminent risk of death, serious injury 
or serious illness and that requires prompt remedial 
action for other patients, users or other persons immedi-
ately, but not later than two working days after becoming 
aware of a new reportable event or of new information in 
relation to an already reported event.
Once all the data are collected, checked and corrected, 
the database is closed, and analyses performed. All data 
transfer, processing and analyses are done using deper-
sonalised data, and all the data sets are protected by pass-
word. In order to promote data quality, the evaluators are 
trained on all the data collection and management proce-
dures and are provided with written instructions by the 
first (EL) and last (MO-C) authors.
To incentivise the completion of the follow-up, the 
patients are given the choice to participate in these assess-
ments at the clinic or via a phone interview with the eval-
uators. When possible, follow-up assessments are also 
conducted with participants that had discontinued the 
treatment or withdrew from the study.
statistical methods
The main analysis will be performed in terms of change 
from baseline to the measurement at treatment comple-
tion using the intention to treat (ITT) population, 
namely all the participants enrolled into the study consid-
ered according to their intial allocation. Complementary 
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analyses will be performed on the per-protocol (PP) 
population with respect to the change from baseline 
to the follow-up assessments at 1, 3 and 6 months after 
completion. These complementary analyses will include 
also the data coming from patients that, after appropriate 
washout period to exclude carry-over, have crossed over 
to the alternative treatment. Both the ITT population 
and the PP population will be specified in detail at the 
Clean file meeting before the database lock and before 
breaking the code. The PP population will be restricted 
to the participants who successfully complete all 15 treat-
ment sessions.
Suitable graphical and numerical summaries will be 
provided for all the variables measured and for corre-
sponding changes in scores.
For the main unadjusted comparison between two 
groups, Fisher’s non-parametric permutation test will be 
used for continuous variables, Mantel-Haenszel χ2 test 
for ordered categorical variables, Fisher’s exact test for 
dichotomous variables and Pearson’s χ2 test for non-or-
dered categorical variables. CIs at 95% for the mean 
differences between two groups will be given when appro-
priate. If differences exist between the two randomised 
groups between baseline variables that could influence 
the outcome variables, a complementary adjusted analysis 
will be performed for these baseline variables.
For adjusted comparison between two groups, anal-
ysis of covariance will be used for continuous outcome 
variables not obviously non-normally distributed with 
intervention/control as independent variable and all 
confounders as covariates.
For analysis of change within groups, Wilcoxon signed-
rank test will be used for continuous variables and sign 
test for ordered categorical and dichotomous variables. 
A complementary mixed model analysis between the two 
treatments regarding the primary efficacy variable with 
centre as random effect will be used to correct for the 
centre-effect in the statistical models.
All correlations will be performed with Spearman’s 
correlation coefficient. The distribution of continuous vari-
ables will be given as mean, SD, median, minimum and 
maximum, and distribution of categorical variables will be 
given as numbers and percentages. All statistical tests will be 
two sided and conducted at the 5% significance level. The 
theory of sequential multiple test procedures will be applied 
for the primary analysis and for secondary analyses. If a test 
gives a significant result at the 5% significance level, the 
total test mass will be transferred to the following number in 
the test sequence until a non-significant result is achieved. 
All these significant tests will be considered confirmative. A 
Statistical Analysis Plan will be written with all detailed statis-
tical analyses specified.
Patient and public involvement
The design of the study was informed by the experience 
with our previous clinical investigation,6 thanks to which 
patients’ priorities, experience and preferences were identi-
fied and used for the development of the research question 
and outcome measures of the current RCT. The burden 
of the control intervention was assessed with a pilot study 
on volunteers with past experience with the experimental 
intervention.
Ethics and dissemination
Research ethics approval
There are no known risks associated with the experimental 
or control treatments, and clinically significant deteriora-
tion is rare. Possible individual benefits include reduced 
PLP, reduced disability associated with pain and improve-
ment in various aspects related to quality of life. This trial 
has been approved by the governing ethical committees of 
each participating country. Important protocol modifica-
tions will be reported in a timely manner to all the relevant 
parties.
Access to data
The principal investigator, MO-C, has full access to all of the 
data in the study except the documents containing the link 
between patient’s identity and their code number, which 
will be accessible only after the completion of the data anal-
yses. MO-C takes responsibility for the integrity of the data 
and the accuracy of the data analysis.
Dissemination policy
Regardless of the significance, direction or magnitude 
of effect, the consortium will publish the findings of this 
study in scientific, peer-reviewed journals and conferences 
following the Consolidated Standards of Reporting Trials 
guidelines. All the clinical investigators will author the scien-
tific article reporting the results of the trial. Results will be 
also disseminated to all the participants of the study with a 
report. No professional writers external to the study will be 
used aside from conventional English proof reading. Access 
to the detailed clinical investigation plan, participant-level 
dataset and statistical code will be granted based on reason-
able requests after the publication of the study.
trial status
This clinical trial is currently in the participant enrolment 
phase. Fourteen patients have been randomised and are 
under treatment at November 2017. It is anticipated that 
full analysis will be finalised in April 2020.
Author affiliations
1Biomechatronics and Neurorehabilitation Laboratory, Department of Electrical 
Engineering, Chalmers University of Technology, Goteborg, Sweden
2Department of Prosthetics and Orthotics, Faculty of Medicine and Health, Örebro 
University Hospital, Örebro, Sweden
3Faculty of Medicine and Health, University Health Care Research Centre, Örebro 
University, Örebro, Sweden
4University Rehabilitation Institute, Ljubljana, Slovenia
5Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
6Department of Rehabilitation Medicine, University of Groningen, University Medical 
Centre Groningen, Haren, Groningen, The Netherlands
7School of Psychology & Centre for Pain Research, National University of Ireland, 
Galway, Ireland
8Centre for Advanced Reconstruction of Extremities, Sahlgrenska University 
Hospital, Gothenburg, Sweden
9Gåskolan/Ortopedteknik, Sahlgrenska Universitetssjukhuset, Goteborg, Sweden
 o
n
 14 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021039 on 16 July 2018. Downloaded from 
9Lendaro E, et al. BMJ Open 2018;8:e021039. doi:10.1136/bmjopen-2017-021039
Open access
10Rehabcenter Sfären, Bräcke Diakoni, Stockholm, Sweden
11Institute of Biomedical Engineering, University of New Brunswick, Fredericton, 
New Brunswick, Canada
12Fysische Geneeskunde en Revalidatie, University Hospital Gent, Gent, Belgium
13Integrum AB, Molndal, Sweden
Acknowledgements  The authors would like to thank the patients that with their 
feedback helped to define the research questions, outcome measures and the 
patient advisers. 
Contributors MO-C conceived the phantom motor execution treatment. MO-C and 
EL reviewed the literature and designed the study. All authors provided feedback 
on the design of the trial. BEM and MP assisted in the selection of psychological 
measure. LB-K and KK-O coordinated the ethical applications. EL and MO-C 
drafted the manuscript. All authors revised the study protocol and approved the 
final manuscript. MO-C is the coordinating investigator of the study and endpoint 
adjudication evaluator. EL is the monitor of the trial, independent from the sponsor, 
and responsible for data management. Each site is constituted by at least a 
principal investigator, a therapist and a blinded evaluator. Investigational sites are 
independent from each other and from the sponsor. 
funding This study was funded by the Promobilia foundation (F16501), VINNOVA 
(Medtech4Health 2016-02290), EFIC Grünenthal Grant (358041552) and Integrum 
AB (sponsor). The sponsor (Integrum AB) provided the devices and materials used 
in this study.
disclaimer Neither the sponsor nor the funders (Promobilia, VINNOVA, EGG) had a 
role in the design of the present protocol.
Competing interests The sponsor of this study (Integrum AB) is a for-profit 
organisation that might commercialise the device used in this study (phantom 
motor execution and phantom motor imagery). MO-C was partially funded by 
Integrum AB. The core technology used in this study has been made freely available 
as open source by MO-C (machine learning, virtual reality and electronics). 
patient consent Not required.
Ethics approval Regionala Etikprövningsnämnden i Göteborg.
provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEfErEnCEs
 1. Dijkstra PU, Geertzen JH, Stewart R, et al. Phantom pain and 
risk factors: a multivariate analysis. J Pain Symptom Manage 
2002;24:578–85.
 2. Clark RL, Bowling FL, Jepson F, et al. Phantom limb pain after 
amputation in diabetic patients does not differ from that after 
amputation in nondiabetic patients. Pain 2013;154:729–32.
 3. Nikolajsen L, Jensen TS, pain PlimbBr J Anaesth 2001;87:107–16.
 4. Batsford S, Ryan CG, Martin DJ. Non-pharmacological conservative 
therapy for phantom limb pain: A systematic review of randomized 
controlled trials. Physiother Theory Pract 2017;33:173–83.
 5. Ortiz-Catalan M, Sander N, Kristoffersen MB, et al. Treatment of 
phantom limb pain (PLP) based on augmented reality and gaming 
controlled by myoelectric pattern recognition: a case study of a 
chronic PLP patient. Front Neurosci 2014;8.
 6. Ortiz-Catalan M, Guðmundsdóttir RA, Kristoffersen MB, et al. 
Phantom motor execution facilitated by machine learning and 
augmented reality as treatment for Phantom Limb Pain. Lancet 
2016;388:2885–94.
 7. Raffin E, Richard N, Giraux P, et al. Primary motor cortex changes 
after amputation correlate with phantom limb pain and the ability to 
move the phantom limb. Neuroimage 2016;130:134–44.
 8. Lendaro E, Mastinu E, Håkansson B, et al. Real-time Classification 
of Non-Weight Bearing Lower-Limb Movements Using EMG to 
Facilitate Phantom Motor Execution: Engineering and Case Study 
Application on Phantom Limb Pain. Front Neurol 2017;8.
 9. MacIver K, Lloyd DM, Kelly S, et al. Phantom limb pain, cortical 
reorganization and the therapeutic effect of mental imagery. Brain 
2008;131(Pt 8):2181–91.
 10. Chan BL, Witt R, Charrow AP, et al. Mirror therapy for phantom limb 
pain. N Engl J Med 2007;357:2206–7.
 11. Moseley GL. Graded motor imagery for pathologic pain: a 
randomized controlled trial. Neurology 2006;67:2129–34.
 12. Bowering KJ, O'Connell NE, Tabor A, et al. The effects of graded 
motor imagery and its components on chronic pain: a systematic 
review and meta-analysis. J Pain2013;14:3–13.
 13. Ortiz-Catalan M, Brånemark R, Håkansson B. BioPatRec: A modular 
research platform for the control of artificial limbs based on pattern 
recognition algorithms. Source Code Biol Med 2013;8:11.
 14. Ortiz-Catalan M, Hkansson B, Brnemark R. Real-Time and 
Simultaneous Control of Artificial Limbs Based on Pattern 
Recognition Algorithms. IEEE Transactions on Neural Systems and 
Rehabilitation Engineering 2014;22:756–64.
 15. Simon AM, Hargrove LJ, Lock BA, et al. Target Achievement 
Control Test: evaluating real-time myoelectric pattern-recognition 
control of multifunctional upper-limb prostheses. J Rehabil Res Dev 
2011;48:619–27.
 16. Melzack R. The short-form McGill Pain Questionnaire. Pain 
1987;30:191–7.
 17. Pollard CA. Preliminary validity study of the pain disability index. 
Percept Mot Skills 1984;59:974.
 18. Melzack R. The McGill Pain Questionnaire: major properties and 
scoring methods. Pain 1975;1:277–99.
 19. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary 
testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life 
Res 2011;20:1727–36.
 20. Nicholas MK. The pain self-efficacy questionnaire: Taking pain into 
account. Eur J Pain 2007;11:153–63.
 21. Nicholas MK, McGuire BE, Asghari A, et al. A 2-item short form of 
the Pain Self-efficacy Questionnaire: development and psychometric 
evaluation of PSEQ-2. J Pain 2015;16:153–63.
 22. McWilliams LA, Kowal J, Wilson KG. Development and evaluation 
of short forms of the Pain Catastrophizing Scale and the Pain Self-
efficacy Questionnaire. Eur J Pain 2015;19:1342–9.
 23. Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: 
Development and validation. Psychol Assess 1995;7:524–32.
 24. Sullivan MJ, Thorn B, Haythornthwaite JA, et al. Theoretical 
perspectives on the relation between catastrophizing and pain. Clin J 
Pain2001;17:52–64.
 25. Spitzer RL, Kroenke K, Williams JBW. Validation and Utility of a Self-
report Version of PRIME-MD. J Am Med Assoc 1999;282:1737–44.
 26. Kroenke K, Spitzer RL, Williams JB. The Patient Health 
Questionnaire-2: validity of a two-item depression screener. Med 
Care 2003;41:1284–92.
 27. Hurst H, Bolton J. Assessing the clinical significance of change 
scores recorded on subjective outcome measures. J Manipulative 
Physiol Ther 2004;27:26–35.
 28. Jones SMW, Lange J, Turner J, et al. Development and Validation 
of the EXPECT Questionnaire: Assessing Patient Expectations of 
Outcomes of Complementary and Alternative Medicine Treatments 
for Chronic Pain. The Journal of Alternative and Complementary 
Medicine 2016;22–936–46.
 29. Mooney TK, Beth M, Gibbons C, et al. Credibility and the Relation of 
Credibility to Therapy Outcome. 2015;24:565–77.
 30. Williams GC, Freedman ZR, Deci EL. Supporting autonomy to 
motivate patients with diabetes for glucose control. Diabetes Care 
1998;21:1644–51.
 31. Saghaei M, Saghaei S. Implementation of an open-source 
customizable minimization program for allocation of patients to 
parallel groups in clinical trials. J Biomed Sci Eng 2011;04:734–9.
 32. Ersland L, Rosén G, Lundervold A. Smievoll a I, Tillung T, Sundberg 
H, et al. Phantom limb imaginary fingertapping causes primary motor 
cortex activation: an fMRI study. Neuroreport 1996;8:207–10.
 33. Hugdahl K, Rosén G, Ersland L, et al. Common pathways in mental 
imagery and pain perception: an fMRI study of a subject with an 
amputated arm. Scand J Psychol 2001;42:269–75.
 34. Lotze M, Flor H, Grodd W, et al. Phantom movements and pain. An 
fMRI study in upper limb amputees. Brain 2001;124(Pt 11):2268–77.
 35. Rosén G, Hugdahl K, Ersland L, et al. Different brain areas activated 
during imagery of painful and non-painful 'finger movements' in a 
subject with an amputated arm. Neurocase2001;7:255–60.
 36. Roux FE, Ibarrola D, Lazorthes Y, et al. Virtual movements activate 
primary sensorimotor areas in amputees: report of three cases. 
Neurosurgery 2001;49:736–41.
 37. Roux FE, Lotterie JA, Cassol E, et al. Cortical areas involved in virtual 
movement of phantom limbs: comparison with normal subjects. 
Neurosurgery 2003;53:1342–53.
 o
n
 14 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-021039 on 16 July 2018. Downloaded from 
